Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Coverage Initiated by Analysts at TD Cowen

Investment analysts at TD Cowen started coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a research note issued to investors on Monday. The firm set a “buy” rating on the stock.

Several other brokerages have also weighed in on DMRA. Wedbush started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday, May 28th. They set an “outperform” rating and a $35.00 target price for the company. Royal Bank Of Canada assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They set an “outperform” rating and a $40.00 price objective for the company. Guggenheim reissued a “buy” rating and issued a $40.00 target price (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. Evercore began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price target on the stock. Finally, UBS Group started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. They issued a “buy” rating and a $45.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Damora Therapeutics, Inc. Common Stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Damora Therapeutics, Inc. Common Stock Stock Performance

DMRA stock opened at $21.01 on Monday. Damora Therapeutics, Inc. Common Stock has a one year low of $2.45 and a one year high of $38.33. The firm has a market cap of $1.29 billion, a PE ratio of -3.77 and a beta of 1.46. The firm’s 50 day moving average price is $24.95 and its 200-day moving average price is $25.31.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.23). Equities research analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth about $76,000. Virtu Financial LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth approximately $49,000. Connective Capital Management LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the third quarter valued at approximately $100,000. Sigma Planning Corp purchased a new position in Damora Therapeutics, Inc. Common Stock in the fourth quarter worth approximately $334,000. Finally, Geode Capital Management LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $266,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.